March 1, 1980Critical Care Medicine
The effect of newer antiarrhythmic drugs on defibrillation threshold
Why the study?
Do clofilium phosphate and bretylium tosylate lower ventricular defibrillation threshold in a canine model?
Population
18 dogs anesthetized with pentobarbital and subjected to repeated fibrillation-defibrillation episodes
Comparison
Clofilium phosphate or bretylium tosylate vs Baseline (30 min before drug injection)
Design
Preclinical
Follow-up
120 min after injection
Authors
Discussion
Loading...
Member takes
Implication
May inform class III agent selection in arrhythmia models; leaves open human defibrillation threshold trials.
Structured PICO
Do clofilium phosphate and bretylium tosylate lower ventricular defibrillation threshold in a canine model?
P
Population
18 dogs anesthetized with pentobarbital and subjected to repeated fibrillation-defibrillation episodes
I
Intervention
Clofilium phosphate (0.34 mg/kg, iv) or bretylium tosylate (10.0 mg/kg, iv)
C
Comparator
Baseline (30 min before drug injection)
O
Outcome
Ventricular defibrillation threshold (current and energy) measured at 15-min intervals up to 120 min after injectionsurrogate
Clofilium phosphate and bretylium tosylate significantly lower ventricular defibrillation thresholds in a canine model, suggesting potential clinical benefit for controlling ventricular arrhythmias.
Cite This Study
Tacker et al. (1980) studied this question.